Fast-Track is a comprehensive approach implemented by health systems working in close collaboration with civil society to deliver evidenceinformed, high-impact services within an enabling environment that protects individual rights and moves society towards the goal of zero discrimination. Fast-Track is guided at the national level ...

INVESTMENT CASES ACCELERATE TRANSFORMATION Investment cases promote the scaling up of optimally effective, rights-based responses that enhance equity and inclusiveness and overcome barriers for the populations most in need of services. SMART INVESTMENTS RESPOND TO SPECIFIC EPIDEMICS AND YIELD HIGH RETURNS Countries are focusing investments on high-burden regions ...

Today’s decision-makers have to make tough investment choices. What is the right level of investment? What is a fair share for HIV prevention? Where resources should be directed? Who should benefit? What is working and what is not? Should we focus on a single solution, ...

This publication is an update of the 2005 guidelines for measuring national HIV prevalence in populationbased surveys of the UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. These guidelines are written for public health surveillance and programme officers responsible for monitoring the HIV epidemic ...

First generation surveillance relied solely on data on AIDS cases and some sentinel studies on HIV prevalence. In 2000, a new strategy named second generation surveillance (SGS) was promoted to tailor surveillance systems to the epidemic state of a country (1). More specifically, the strategy ...

People living with the human immunodeficiency virus (HIV) are 29 times (26-31) more likely to develop tuberculosis (TB) disease as people without HIV and living in the same country. TB is a leading cause of death among people living with HIV, accounting for one in ...

Recommendations for the selection and use of HIV antibody tests were first issued by WHO in 1992.1 Since then the range of HIV antibody tests available has expanded. New types of assays have been developed and the overall quality has improved. HIV tests for other ...

WHO/UNAIDS Consultation with manufacturers. March 2015, Geneva, Switzerland Key Points • The IATT Optimal Formulary is designed to guide selection and procurement of paediatric ARV’s around a subset of optimal products • Consolidation of demand stabilizes supplies of paediatric ARVs • Success requires global consensus, cooperation with the manufacturers, ...